source
- Roivant Sciences launches first solo drug, Lisraya, after FDA approval for dermatomyositisRoivant Sciences, which operates a hub-and-spoke subsidiary model, is stepping into the commercial arena with its inaugural solo product launch. The FDA has granted approval to the oral TYK2/JAK i…
- CSL agrees $355M upfront deal to co-develop Alentis anti-fibrosis drug for kidney and liverCSL, an Australian drugmaker, announced a partnership with Alentis Therapeutics that includes a $355 million upfront payment. Under the agreement, CSL will co-develop Alentis's anti-fibrosis candi…